GC
TXMD icon

Guggenheim Capital’s TherapeuticsMD TXMD Stock Holding History

Guggenheim Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-214
Closed -$4K – 2134
2022
Q1 		$4K Buy
+214
New +$3.37K ﹤0.01% 2114
2019
Q2 		– Sell
-12,535
Closed -$3.05M – 2178
2019
Q1 		$3.05M Hold
12,535
– – 0.02% 881
2018
Q4 		$2.39M Buy
12,535
+6,049
+93% +$1.48M 0.02% 948
2018
Q3 		$2.13M Buy
+6,486
New +$1.99M 0.01% 1202
2018
Q2 		– Sell
-828
Closed -$201K – 2602
2018
Q1 		$201K Sell
828
-636
-43% -$178K ﹤0.01% 2617
2017
Q4 		$441K Sell
1,464
-63
-4% -$17.5K ﹤0.01% 2398
2017
Q3 		$404K Sell
1,527
-125
-8% -$36.1K ﹤0.01% 2463
2017
Q2 		$435K Buy
1,652
+269
+19% +$67.4K ﹤0.01% 2445
2017
Q1 		$498K Buy
1,383
+657
+90% +$203K ﹤0.01% 2380
2016
Q4 		$209K Buy
726
+418
+136% +$130K ﹤0.01% 2681
2016
Q3 		$105K Buy
308
+78
+34% +$28.5K ﹤0.01% 2723
2016
Q2 		$98K Buy
+230
New +$94.8K ﹤0.01% 2729
2015
Q2 		– Sell
-214
Closed -$65K – 3096
2015
Q1 		$65K Buy
+214
New +$52.2K ﹤0.01% 2901
2014
Q1 		– Sell
-728
Closed -$190K – 3359
2013
Q4 		$190K Buy
728
+434
+148% +$95K ﹤0.01% 2862
2013
Q3 		$43K Buy
+294
New +$35.5K ﹤0.01% 2953

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Guggenheim Capital's TXMD Position: Q2 2022 in Review

Guggenheim Capital sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 214 shares — an estimated $4K sold.

Guggenheim Capital first reported a position in TXMD in Q3 2013 and held it in 15 quarters. The position peaked at $3.05M in Q1 2019. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Guggenheim Capital reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Guggenheim Capital sold 214 TherapeuticsMD shares in Q2 2022, an estimated $4K.
  • Guggenheim Capital first reported a position in TherapeuticsMD in Q3 2013 and held it in 15 quarters.
  • Guggenheim Capital's TherapeuticsMD position peaked at $3.05M in Q1 2019.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Guggenheim Capital's 13F filing for Q2 2022, filed 15 Aug 2022.